BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38534952)

  • 1. Real-World Evidence of the Impact of the COVID-19 Pandemic on Lung Cancer Survival: Canadian Perspective.
    Agulnik J; Kasymjanova G; Pepe C; Friedmann J; Small D; Sakr L; Wang H; Spatz A; Sultanem K; Cohen V
    Curr Oncol; 2024 Mar; 31(3):1562-1571. PubMed ID: 38534952
    [No Abstract]   [Full Text] [Related]  

  • 2. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center.
    Kasymjanova G; Rizzolo A; Pepe C; Friedmann JE; Small D; Spicer J; Lecavalier-Barsoum M; Sultanem K; Wang H; Spatz A; Cohen V; Agulnik JS
    Curr Oncol; 2022 Nov; 29(11):8677-8685. PubMed ID: 36421337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome.
    Park H; Dahlberg SE; Lydon CA; Araki T; Hatabu H; Rabin MS; Johnson BE; Nishino M
    Oncologist; 2019 Aug; 24(8):e749-e754. PubMed ID: 30696724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315).
    Sebastian M; Eberhardt WEE; von der Heyde E; Dörfel S; Wiegand J; Schiefer C; Losem C; Jänicke M; Fleitz A; Zacharias S; Kaiser-Osterhues A; Hipper A; Dietel C; Bleckmann A; Benkelmann R; Boesche M; Grah C; Müller A; Griesinger F; Thomas M;
    Int J Cancer; 2024 Jun; 154(11):1967-1978. PubMed ID: 38329180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of pembrolizumab for advanced nonsmall cell lung cancer: before and during the COVID-19 pandemic.
    Ksienski D; Gupta S; Truong PT; Bone J; Chan A; Alex D; Hart J; Pollock P; Patterson T; Clarkson M; Dissanayake D; Sonke E; Lesperance M
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):2951-2961. PubMed ID: 35834010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea.
    Park JY; Lee YJ; Kim T; Lee CY; Kim HI; Kim JH; Park S; Hwang YI; Jung KS; Jang SH
    BMC Cancer; 2020 Oct; 20(1):1040. PubMed ID: 33121456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
    Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
    BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the COVID-19 pandemic on non-small-cell lung cancer pathologic stage and presentation.
    Keogh JAJ; Chhor AD; Begum H; Akhtar-Danesh N; Finley C
    Can J Surg; 2022; 65(4):E496-E503. PubMed ID: 35926883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of prognostic impact of number of extrathoracic metastases according to the eighth TNM classification: a single-institution retrospective study in Japan.
    Sakai K; Kuramoto J; Kojima A; Nishimura H; Kuwabara Y; Toda M; Kobayashi Y; Kikuchi S; Hirata Y; Mikami-Saito Y; Mikami S; Kyoyama H; Moriyama G; Gemma A; Uematsu K
    Int J Clin Oncol; 2019 Dec; 24(12):1549-1557. PubMed ID: 31452019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world treatment patterns and survival in stage IV non-small-cell lung cancer in Canada.
    Seung SJ; Hurry M; Walton RN; Evans WK
    Curr Oncol; 2020 Aug; 27(4):e361-e367. PubMed ID: 32905294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wait Times and Survival in Lung Cancer Patients across the Province of Quebec, Canada.
    Denault MH; Labbé C; St-Pierre C; Fournier B; Gagné A; Morillon C; Joubert P; Simard S; Martel S
    Curr Oncol; 2022 Apr; 29(5):3187-3199. PubMed ID: 35621649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Center: A Retrospective Chart Review.
    Kasymjanova G; Anwar A; Cohen V; Sultanem K; Pepe C; Sakr L; Friedmann J; Agulnik JS
    Curr Oncol; 2021 Oct; 28(6):4247-4255. PubMed ID: 34898542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer center.
    Tiu AC; Potdar R; Djibo DA; Masab M; Dourado C
    Med Oncol; 2018 Jun; 35(7):109. PubMed ID: 29915891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of the COVID-19 Pandemic on the Diagnosis and Treatment Characteristics of Operated Lung Cancer Patients.
    Arak H; Eronat O; Dogan I; Aydin ES; Aytekin A
    J Coll Physicians Surg Pak; 2023 Nov; 33(11):1271-1277. PubMed ID: 37926880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of COVID-19-related health care disruptions on pathologic cancer staging during the first pandemic year: a retrospective cohort study from March 2018 to March 2021.
    Tran C; Cipriano LE; Driman DK
    CMAJ Open; 2023; 11(3):E475-E484. PubMed ID: 37279981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of Lung Cancer Patient Characteristics and Treatment Strategies in the Pandemic Covid-19 Year.
    Crvenkova S; Jakimovki D; Ristovski V
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2023 Mar; 44(1):105-115. PubMed ID: 36987767
    [No Abstract]   [Full Text] [Related]  

  • 18. A study of the efficacy and toxicity outcomes of extended durvalumab dosing in patients with stage III unresectable non-small cell lung cancer (NSCLC) during the COVID-19 pandemic.
    Hanna L; Moffat GT; Hopman W; Gaudreau PO; Fung AS
    Cancer Treat Res Commun; 2023; 34():100678. PubMed ID: 36608489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry.
    Metzenmacher M; Griesinger F; Hummel HD; Elender C; Schäfer H; de Wit M; Kaiser U; Kern J; Jänicke M; Spring L; Zacharias S; Kaiser-Osterhues A; Groth A; Hipper A; Zaun G; Dörfel S; Güldenzoph B; Müller L; Uhlig J; Thomas M; Sebastian M; Eberhardt WEE;
    Eur Respir J; 2023 Feb; 61(2):. PubMed ID: 36180086
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.